Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis

ABSTRACT

The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function. Here we demonstrate that specific glyceollins, isolated from elicited soy, displayed anti-estrogenic activity, suppressing basal and estrogen stimulated colony formation of ER-positive estrogen dependent breast cancer cells and inhibiting ER-dependent gene expression of progesterone receptor (PgR) and stromal derived factor-1 (SDF1/CXCL12). Examining the effects of glyceollin on in vivo tumor formation/growth we demonstrate the ability of glyceollins to significantly suppress basal and estrogen-stimulated tumor growth of ER-positive MCF-7 breast and BG-1 ovarian carcinoma cells in ovariectomized female nude mice. We further demonstrate that the effects of glyceollins on suppression of tumor growth correlate with inhibition of estrogen stimulated PgR expression. In contrast to the uterotropic activity of tamoxifen the glyceollins displayed no uterine agonist activity. The Glyceollin (I-III) compounds may represent an important component of the health effects of soy as well as represent novel anti-estrogens useful in the prevention or treatment of breast and ovarian carcinoma.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to increased biosynthesis and isolation ofthe isoflavonoid phytoalexin compounds, Glyceollins I, III and II, insoy plants grown under stressed conditions, a composition containingsaid glyceollin(s), a selective estrogen receptor modulator, and amethod of treating and preventing breast and ovarian carcinoma whileinhibiting selective estrogen receptor modulator-induced uterotrophiceffects.

2. Description of the Relevant Art

During endocrine therapy, the antiestrogen tamoxifen has been shown toprevent pre- and postmenopausal breast cancer and to be a beneficialadjuvant therapy for women with estrogen receptor-positive tumors.Ultimately tumors can develop resistance, and in the case of theantiestrogen tamoxifen, tamoxifen can increase the risk of endometrialcancer (Brown, K. 2002. Expert Opin. Drug Saf. 1: 253-267).Consequently, efforts have been made to develop new antiestrogens fromboth synthetic and natural sources. Many naturally occurring agents,particularly flavonoids, have shown chemopreventive and anticancerpotential in a variety of in vitro and in vivo models (Diel et al. 2001.Human Reproduction 16(5): 997-1006; Barnes, S. 1997. Breast Cancer Res.Treat. 46: 169-179; Aronson et al. 1999. Nutr. Cancer 35(2): 130-136).The isoflavone genistein has received much attention over the last fewyears as a potential anticancer agent due to its wide-range effects on anumber of cellular processes. The chemopreventive effects of genisteinand other flavonoids have spurred research to discover other naturallyoccurring flavonoids in soybean and other plants with anticanceractivities.

Phytoalexins constitute a chemically heterogeneous group of substancesbelonging to the various sub-classifications of flavonoids. Phytoalexinsare low molecular weight antimicrobial compounds that are synthesized denovo and accumulate in plants as a stress response (Darvill et al. 1984.Ann. Rev. Plant Physiol. 35: 243-275; Paxton, J. D. 1991. In: EmergingProblems Resulting from Microbial Contamination, Sharma et al. (Eds.),CRC Press, Boca Raton, Fla.). The phytoalexins are products of a plant'ssecondary metabolism, and often accumulate at infection sites atconcentrations that inhibit fungal and bacterial growth (Darvill et al.,supra; Paxton, J. D., supra). Countless stress factors or physicalstimuli induce phytoalexin accumulation including freezing, ultravioletlight exposure and exposure to microorganisms. In addition, compoundsreferred to as elicitors, either abiotic or biotic, can stimulate thebiosynthesis of phytoalexins. Given that the biosynthesis ofisoflavonoids, particularly phytoalexins, can be regulated by externalfactors, the type and amount of hormonally active phytochemicals mayvary form source to source. In soybean, several phytoalexins,particularly the glyceollins, are produced under conditions of stress.The glyceollins (mixture of Glyceollin I, II, and III) have beenproduced in high concentrations using several elicitors and haveantimicrobial activity against several plant pathogens (Darvill et al.,supra; Graham et al. 1990. Mol. Plant-Microbe Interactions 3(3):157-166; Daniel et al. 1999. Environ. Health Perspectives 107: 109-114;Rivera-Vargas et al. 1993. Phytochem. 32 (4): 851-857; Rizk et al. 1984.Qual. Plant Foods Human Nutr. 34 (3): 203-210; Bhattacharyya et al.1986. Physiol and Mol. P1. Pathol. 29: 227-237; Graham et al. 1991. Mol.Plant-Microbe Interactions 4(1): 60-68).

Studies linking consumption of a phytochemical rich diet to a decreasedrisk of hormone-dependent tumors such as breast cancer suggest a rolefor these compounds in prevention or suppression of cancer. In regardsto soy rich diets, the two major phytochemicals present are theisoflavones genistein and daidzein, which exist in the aglycone orconjugated form. Studies support the view that isoflavones may haveprotective effects with regard to estrogen-dependent cancer,particularly breast cancer. A role for isoflavones in thechemoprevention or potential treatment of breast carcinoma has beenstudied (Constantinou et al. 1998. Am J. Clin. Nutr. 68 (6 Suppl.):1426S-1430S; Hewitt et al. 2003. Cancer Left. 192 (2): 133-143). Severalanimal studies suggest that isoflavones retard cancer development.Newborn female rats treated neonatally with genistein and then exposedto a carcinogen had increased latency and decreased incidence andmultiplicity of mammary tumors compared with vehicle-treated animals(Lamartiniere et al. 1995a. Carcinogenesis 16(11): 2833-2840;Lamartiniere et al. 1995b. Proc. Soc. Exp. Biol. Med. 208 (1):120-123).

However, studies examining dietary genistein effects onestrogen-responsive human breast carcinoma cells implanted into micesuggest the agonist activity of genistein may enhance tumor growth(Barnes, supra). These animal studies using isolated isoflavones haveyielded contradictory results as to the effects of these on tumor growthand chemoprevention suggesting a complex role for the effects offlavonoids on cancer cells. The effects of estrogenic compounds such asdaidzein or genistein on breast cancer cell proliferation andtumorigenesis may therefore be in part complicated by a complex activityof both agonistic effects on estrogen receptor (ER) function along withtyrosine kinase inhibitory activity at higher doses.

Soybeans grown under stressed conditions were examined to determine ifadditional unidentified compounds isolated from soybean could furtherelucidate the role of phytochemicals in breast cancer tumorigenesis andestrogen receptor function. Through these studies, we described theisolation of the glyceollins as a mixture of three isomers (GlyceollinI, II, and III) from stressed soybeans. Functional analysis of thesecompounds demonstrated that the glyceollins displayed a markedantiestrogenic effect on estrogen receptor signaling; direct binding tothe estrogen receptor correlated with a comparable suppression of17β-estradiol (E2)-induced proliferation in MCF-7 cells (Burow et al.2001. J. Endocrinol. 86 (4): 1750-1758). Furthermore, in contrast toother isoflavones found in soy, no estrogenic activity was observed withthe glyceollins in vitro. From these studies, we hypothesized that theglyceollins represented novel antiestrogenic flavonoids naturallyproduced by soy that may be relevant to human health.

There is a need to develop new antiestrogens from both synthetic andnatural sources. Further, there is a need to reduce the risks ofestrogenic effects as has been observed with tamoxifen in uterinetissue. Thus, in view of the antiestrogenic activity of the glyceollinsin vitro and its lack of estrogenic activity, the efficacy of theglyceollins as a novel therapy in vivo was determined.

SUMMARY OF THE INVENTION

We have isolated glyceollins from elicited soy and discovered thatglyceollins are novel antiestrogens useful in the prevention andtreatment of breast and ovarian carcinoma.

In accordance with this discovery, it is an object of the invention toprovide isolated glyceollins (Glyceollin I, II, and III) from elicitedsoy.

It is a further object of the invention to provide a compositioncontaining glyceollin for preventing or minimizing the development orgrowth of breast cancer and ovarian cancer.

It is another object of the invention to provide a method for preventingor minimizing the development or growth of breast cancer and ovariancancer in a mammal, particularly a human.

Also part of this invention is a kit, comprising a glyceollin-containingcomposition for preventing or minimizing the development or growth ofbreast cancer and ovarian cancer.

Other objects and advantages of this invention will become readilyapparent from the ensuing description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the structures of Glyceollins I, II, and III.

FIG. 2 shows the effects of glycebllins in the in vitro MCF-7 colonyassay.

FIG. 3 depicts the effects of the glyceollins on breast tumor growth invivo (mm³, group means±SEM). MCF-7 breast carcinoma cells were implantedin the mammary fat pad of nu/nu female ovariectomized mice in thepresence or absence of E2-pellet. Mice were treated with or without s.c.injection of glyceollins (20 mg/kg/animal/day) for 20 days with tumorgrowth monitored every other day. Treatment, trial day, and treatment bytrial day interactions are statistically significant (p<0.001, power=1.0by repeated measures two-way ANOVA). Different letters indicatesignificant differences among groups on a given treatment day (byHolm-Sidak post-hoc multiple pair-wise comparisons testing).

FIG. 4 shows the effects of the glyceollins on ovarian tumor growth invivo (mm³, group means±SEM). BG-1 ovarian carcinoma cells were implantedin the mammary fat pad of nu/nu female ovariectomized mice in thepresence or absence of E2-pellet. Mice were treated with or without s.c.injection of glyceollins (20 mg/kg/animal/day) for 20 days with tumorgrowth monitored every other day. Treatment, trial day, and treatment bytrial day interactions are statistically significant (p<0.001, power=1.0by repeated measures two-way ANOVA). Different letters indicatesignificant differences among groups on a given treatment day (byHolm-Sidak post-hoc multiple pair-wise comparisons testing).

FIG. 5 depicts progesterone receptor (PR) expression in MCF-7 and BG1tumor explants, as determined by immunohistochemistry. E2 treatmentsignificantly increased PR compared to control, while glyceollin-alonehad no effect. PR in E2+glyceollin was significantly lower than forE2-alone in MCF-7 cells and did not differ significantly from controltreatment for either cell line. Treatments included 4-5 animals pergroup. Different letters indicate significant differences between groups(p<0.05 by ANOVA).

FIG. 6 depicts the effect of E2, glyceollin, tamoxifen, and tamoxifenwith glyceollin, and E2 with glyceollin on uterine weights.

FIGS. 7A-C depict glyceollin effects on uterine morphology in nu/numice. FIG. 7A depicts the effects of glyceollin on uterine area, FIG.7B, on uterine diameter, and FIG. 7C, on uterine epithelial height. E2significantly increased uterine size and epithelial height, whileglyceollin-alone had no effect on any of the measures. Uterine area anddiameter were significantly lower for E2+glyceollin compared to E2alone. Treatments included 4-5 animals per group. Histomorphometricmeasures were quantitated from H&E-stained slides. Different lettersindicate significant differences between groups (p<0.05 by ANOVA).

FIG. 8 shows sections of mouse uteri evaluated to assess whetherglyceollin treatment had estrogen-like effects on other reproductivetissues. On histology, uteri from control and glyceollin-treated animalswere diffusely atrophic and could not be distinguished morphologically.

DETAILED DESCRIPTION OF THE INVENTION

This invention describes the increased biosynthesis of the isoflavonoidphytoalexin compounds, Glyceollins I, II and III, in soy plants grownunder stressed conditions (elicited soy) and their marked antiestrogeniceffects on estrogen receptor function. To fully understand the role ofglyceollins' anti-estrogenic and anti-cancer properties, we used thewell-established model of MCF-7 and BG-1 tumor formation inimmunocompromised female ovariectomized nu/nu mice to examine theeffects of glyceollins on both basal and estrogen-stimulated growth ofxenografted tumor cells. In this model, using the ER-positive andestrogen-dependent MCF-7 breast and BG-1 ovarian carcinoma cell lines,the in vivo antiestrogenic activity of the glyceollins has beenestablished.

As used herein, the term “ER” refers to “estrogen receptor”. The terms“breast cancer” and “breast carcinoma” refer to any cancer having itsorigin in breast cells, and includes metastatic and local forms ofbreast cancer (node negative and node positive), as well as ER positiveand ER negative forms of breast cancer. The terms “ovarian cancer” and“ovarian carcinoma” refer to all stages of ovarian cancer and includesmetastatic and local forms of ovarian cancer, as well as ER positive andER negative forms of ovarian cancer. The terms “estrogenic effectsobserved in uterine tissue” and “uterotrophic effect” means the increasein uterine size that can be secondary to proliferation of uterineepithelial cells, which frequently is a side effect of administration ofselective estrogen receptor modulators to women, and which appears to bedirectly related to development of endometrial cancer. The term“minimize” or “reduce”, or a derivative thereof, includes a complete orpartial inhibition of a specified biological effect (which is apparentfrom the context in which the term minimize is used). The term“glyceollin” may mean both a single glyceollin and plural glyceollinswhen the glyceollin is defined as at least one of a selected group ofglyceollins. “SERM” means a selective estrogen receptor modulator andits physiologically acceptable salts, other than tamoxifen, which is acompound which produces estrogen antagonist effects in one or moredesired target tissues (e.g. breast tissue and uterine tissue), whileproducing either estrogen agonist effects or minimal agonism in othernon-target tissues. “Tamoxifen” refers to the clinically utilizedantiestrogen.

The glyceollin compounds used in the compositions and methods of thepresent invention are naturally occurring substances which may be foundin plants such as soybeans that are stressed or that have been treatedwith elicitors. The glyceollin compounds may be isolated from the plantsources in which they naturally occur after treatment with an elicitor,or may be synthetically prepared by processes known in the art.

It is preferred to extract the glyceollins useful in the compositionsand methods of the present invention from the plant materials in whichthey naturally occur. A preferred method of isolating the glyceollincompounds is to extract the plant materials with an alcohol, preferablymethanol or ethanol, or an aqueous methanolic solution, to remove theglyceollins from the plant material. It is preferred to comminute theplant material before extracting the glyceollin compounds to maximizerecovery of glyceollin compounds from the plant material. The glyceollincompounds are isolated from the extract by conventional separationprocedures, such as high performance liquid chromatography, HPLC.

In a preferred embodiment, the glyceollin compounds are isolated from asoy material. Soy materials from which the glyceollin compounds can beisolated include elicitor-treated: soy seeds, soybeans, dehulledsoybeans, soy cotyldeons, soy leaf tissue, soy roots, and soyhypocotyls. In one embodiment, the glyceollins are extracted from soyseeds, with a low molecular weight organic extractant, preferably analcohol, ethyl acetate, acetone, or ether, and most preferably aqueousethyl alcohol or methyl alcohol

Here we demonstrate that specific glyceollins, isolated from elicitedsoy, displayed antiestrogenic activity, significantly suppressing basaland estrogen-stimulated colony formation of ER-positive estrogendependent breast cancer cells and inhibiting ER-dependent geneexpression of progesterone receptor (PgR) and stromal derived factor-1(SDF1/CXCL12). Glyceollins inhibited the growth of human ER-positivebreast cancer (MCF-7) and ovarian cancer (BG-1) cells injectedsubcutaneously in female athymic ovariectomized nude mice.

The MCF-7 and BG-1 cancer cell lines are fully estrogen-dependent forgrowth in ovariectomized nude mice. The glyceollins displayed littleestrogenic activity in bioassays, and the in vitro antiestrogenicactivity observed at 10 μM provided evidence for inhibition ofestrogen-dependent human breast and ovarian carcinomas xenografted intoimmunoincompetent (nude) mice. Glyceollins injected subcutaneously with17β-estradiol significantly reduced MCF-7 and BG-1 tumor volumescompared to control groups with estradiol only. At day 20 in Glyceollintreatments with added 17β-estradiol, MCF-7 tumor volume was reduced53.4%, and BG-1 tumor volume was reduced 73.1% (See Example 5). Theability of Glyceollins to also suppress PgR expression in MCF-7 BG-1cells further exemplifies the antiestrogenic activity of thesecompounds. Thus, our earlier studies showing the ability of theglyceollins to antagonize the effects of 17β-estradiol in vitro are alsoobserved for breast and ovarian cancer models in vivo.

The uterotrophic assay that utilizes estrogen-induced growth of theuterus in ovariectomized mice is one of the principal assays used toevaluate the estrogenic and antiestrogenic properties of isoflavones.Several isoflavones, including genistein, have demonstrated agonistactivity in the uterine (Whitten et al. 1994. Steroids 59: 443-449; Dielet al., supra). In these same animals treated for 20 days with vehicle,estradiol, glyceollin or estrogen+glyceollin, uterine size andmorphology was examined. In the present study, the glyceollins aloneshowed no agonist uterotrophic activity. However, glyceollin treatmentantagonized the 17β-estradiol effects on the uterus, significantlyreducing uterine area and diameter, but non-significantly reducedoverall uterine fixed weight. The ability of the glyceollins to functionas an estrogen antagonist in the uteri in mice is a distinct advantagewhen compared to other phytoestrogens and tamoxifen. In several studiestamoxifen has increased uterine weight and acts as an agonist in theuteri (Stygar et al. 2003. Reprod. Biol. Endocrinol. 1: 40-47; Nunez eta. 2004. Clin. Cancer Res. 10: 5375-5380). In comparison, the ability oftamoxifen alone to increase uterine fixed weight over control was notobserved with glyceollins at 20 days. These results suggest that theglyceollins may be functioning as phyto-SERMs (Selective EstrogenReceptor Modulators) selectively antagonizing ER function in atissue-type specific manner. Our data indicate that glyceollins in vivoinhibit the growth of human breast and ovarian cancer xenografts andfunction as phyto-SERMs, antagonizing breast and uterine epithelialproliferation.

The present invention is a composition useful for preventing orminimizing the development or growth of breast and ovarian cancer. Thecomposition contains glyceollins, selective estrogen receptormodulators. The glyceollin-containing material necessary to formcompositions in accordance with the present invention may be obtained asdescribed above. The composition contains from about 1% to about 99%glyceollin, by weight of biologically active ingredients.

The glyceollin is present in the composition in an amount sufficient toprevent, minimize, or reverse the development or growth of breast cancerand/or ovarian cancer in a woman. Preferably at least glyceollin ispresent at a concentration of 100 nM in the composition, more preferablyat a concentration from about 100 nM to about 50 μM. In a most preferredembodiment, the glyceollin is present in the composition in an amountsufficient to prevent, minimize, or reverse the development or growth ofbreast cancer and/or ovarian cancer by itself.

In another preferred embodiment, the glyceollin is present in thecomposition in an amount sufficient to prevent or minimize thecomposition's SERM-induced uterotrophic effects when the composition isadministered to a woman. The glyceollin should be present in a ratio ofglyceollin:SERM of from about 0.25:1 to about 100:1 by weight, and morepreferably from about 0.5:1 to about 50:1 by weight, to be present inthe composition in an amount sufficient to prevent or minimize thecomposition's SERM induced uterotrophic effects. In a most preferredembodiment, the glyceollin is present in the composition in an amountsufficient to augment the composition's SERM-induced prevention orminimization of the development or growth of breast cancer and/orovarian cancer and to prevent or minimize the composition's SERM-induceduterotrophic effects when the composition is administered to a woman.

A composition in accordance with the present invention containing a SERMand glyceollin(s) can be prepared by conventional procedures forblending and mixing compounds. Preferably, the composition also includesan excipient, most preferably a pharmacuetical excipient. Compositionscontaining an excipient and incorporating the SERM and glyceollin can beprepared by procedures known in the art. For example, the glyceollin, orthe composition containing SERM and the glyceollin, can be formulatedinto tablets, capsules, powders, suspensions, solutions for oraladministration and solutions for parenteral administration includingintravenous, intradermal, intramuscular, and subcutaneousadministration, and into solutions for application onto patches fortransdermal application with common and conventional carriers, binders,diluents, and excipients.

Inert pharmaceutically acceptable carriers useful to form pharmaceuticalcompositions in accordance with the present invention include starch,mannitol, calcium sulfate, dicalcium phosphate, magnesium stearate,silicic derivatives, and/or sugars such as sucrose, lactose, andglucose. Binding agents include carboxymethyl cellulose and othercellulose derivatives, gelatin, natural and synthetic gums includingalginates such as sodium alginate, polyethylene glycol, waxes and thelike. Diluents useful in the invention include a suitable oil, saline,sugar solutions such as aqueous dextrose or aqueous glucose, DMSO, andglycols such as polyethylene or polypropylene glycol. Other excipientsinclude lubricants such as sodium oleate, sodium acetate, sodiumstearate, sodium chloride, sodium benzoate, talc, and magnesiumstearate, and the like; disintegrating agents including agar, calciumcarbonate, sodium bicarbonate, starch, xanthan gum, and the like; andadsorptive carriers such as bentonite and kaolin. Coloring and flavoringagents may also be added to the pharmaceutical compositions.

EXAMPLES

Having now generally described this invention, the same will be betterunderstood by reference to certain specific examples, which are includedherein only to further illustrate the invention and are not intended tolimit the scope of the invention as defined by the claims.

Example 1 Soybean Treatment and Harvesting

Aspergillus sojae (S RRC 1125) cultures were grown at 25° C. in the darkon potato dextrose agar. After 5 days, inoculum was prepared byharvesting conidia (3.4×107/ml) in 15 ml sterile, distilled H₂O. Seedsfrom commercial soybean variety Asgrow 5902 were surface-sterilized for3 min in 70% ethanol followed by a quick deionized-H₂O rinse and two 2min rinses in deionized-H₂O. Seeds were presoaked in steriledeionized-H₂O for 4-5 hr, then chopped for 2 min in a Cuisinart foodprocessor. A. sojae spore suspension (300 μl) was applied to the cutsurface of seeds on each tray. All trays were stored at 25° C. in thedark for three days, rinsed with water to remove spores, and oven driedat 40° C. for 24 hrs. Seeds were ground using a Waring blender beforeextraction.

Example 2 Isolation of Glyceollins

A mixture of Glyceollins I, II, and III were isolated using a proceduredeveloped at the Southern Regional Research Center (ARS, USDA, NewOrleans, La.). Soybean seeds (1 kg) were sliced and inoculated withAspergillus soiae, as in Example 1. After three days, the glyceollinswere extracted from the inoculated seeds with methanol (1 liter). TheGlyceollins were isolated using preparative scale HPLC using two Waters25 mm 10 μm particle size μBondapak C₁₈ radial compression columnsegments combined using an extension tube. HPLC was performed on aWaters 600E System Controller combined with a Waters UV-VIS 996detector. Elution was carried out at a flow rate of 8.0 ml/min with thefollowing solvent system: A+acetonitrile, B=water; 5% A for 10 min, then5% A to 90% A in 60 min followed by holding at 90% A for 20 min. Theinjection volume was 20 ml. The fraction containing the glyceollins wasconcentrated under vacuum and freeze-dried. The glyceollins wereconfirmed by UV-VIS spectrophotometry. A mixture of Glyceollins I (68%),III (21%), and III (11%) (FIG. 1) were isolated and used in animaltesting. The solvents acetonitrile (HPLC grade) and methanol werepurchased from Aldrich Chemical Company. Water was obtained using aMillipore system and used during sample preparation procedures and HPLCanalyses.

Example 3 Cell Culture; In Vitro Colony Assay

The MCF-7N cell variant is a subclone of MCF-7 cells from the AmericanType Culture Collection (Manassas, Va.) that was generously provided byLouise Nutter (University of Minnesota, Minneapolis, Minn.) and has beenpreviously described (Graham et al., supra). The BG-1 cell line has beenpreviously described. MCF-7 and BG-1 cells were grown in Dulbecco'smodified minimal medium (pH 7.4; Life Technologies, Inc., Grand Island,N.Y.) supplemented with 10% fetal bovine serum (Hyclone, Salt Lake City,Utah). For studies with estrogen, the cells were cultured in mediumsupplemented with 5% charcoal-stripped fetal bovine serum. The cellswere incubated at 37° C. in an atmosphere of 5% CO₂ and air.

MCF-7 cells are plated at 10³/well in 6 well Cluster dishes, andincubated overnight. Cells are cultured and treated in DMEM withoutphenol red; phenol red interacts with estrogen receptors. Treatment andcontrol plates were incubated at 37° C., 5% CO₂. Plates were observedperiodically. When colonies were of a size of 50 cells or more, at Day14, cells were fixed with glutaraldehyde for 30 min at 37° C., washed,and stained with Crystal violet (0.4%) for 1 hr. Colonies were countedmanually. This method is used to study the effects of chemical orphysical agents on cell survival and proliferation; 1 colony=1 cell.

The antiestrogenic activity of a mixture of Glyceollins (I, II, and IIIshown in FIG. 1) was previously described using a combination of invitro assays (Burow et al., supra). Analysis of this mixture by HPLCrevealed a relative percentage composition of Glyceollin I (68%),Glyceollin II (21%) and Glyceollin III (11%) in this mixture. Aclonogenicity assay was used to examine the effects of a mixture ofGlyceollins on MCF-7 breast carcinoma cell proliferation and survival(FIG. 2). As expected, treatment of MCF-7 cells with estrogen enhancedcolony formation. Estradiol-stimulated growth of MCF-7 cells was reducedin a dose-dependent manner in experiments in which cells were treatedwith estradiol (1 nM) together with glyceollin at doses ranging from 10μM to 50 μM. Glyceollins together with a lower concentration ofestradiol (0.1 nM) also reduced MCF-7 growth. Treatment with increasingconcentrations of Glyceollin I-III reduced both basal-(vehicle-) inducedcolony formation as well as estrogen-stimulated clonogenicity. Anincrease in colony formation above control levels was observed whenusing the glyceollins at 10 μM.

Example 4 Treatment Protocols

Immune compromised (nu/nu) female, ovariectomized mice (29-32 days old)were obtained from Charles-River Laboratories (Wilmington, Mass.). Theanimals were allowed a period of adaptation in a sterile andpathogen-free environment. Cages, bedding, food, and water wereautoclaved before use. Animals were housed five per cage and receivedphytoestrogen-free sterile food and water ad libitum. Mice receivedsubcutaneous inoculations under anesthesia (Isofluorane and Oxigene)delivered by mask. For animals receiving estradiol, an estradiol pellet(0.72 mg, 60 day release, Innovative Research) was implantedsubcutaneously in the lateral area of the neck in the middle pointbetween the ear and shoulder using a precision trochar (10 gauge). MCF-7and BG-1 cells in the exponential phase of growth, were harvested usingPBS/EDTA solution and washed. Viable cells (5×10⁶) in a 50 μl sterilePBS suspension were mixed with 100 μl Matrigel (BD Biosciences, Bedford,Mass.). Cells in Matrigel were injected bilaterally in the mammary fatpad (MFP) through a 5 mm incision at the hypogastrium area, and theincision was closed using staples. The glyceollin mixture was suspendedin a solution of DMSO (1/3 volume) and propylene glycol (2/3 volume) andwas administered subcutaneously in the dorsal area at 20 mg/kg/mouse/dayfor 20 days starting at time of tumor implantation (Day 1). Tumor sizewas measured every two days using calipers. The volume of the tumor wascalculated using the following formula: 4/3 π LM², where M is thesmaller radius.

Example 5 Tumor Growth in Glyceollin Treated MCF-7 and BG-1 XenograftMice

The in vivo effects of glyceollins on tumor growth formation weredetermined. MCF-7 or BG-1 cells were implanted into the mammary fat padof female ovariectomized nude mice. Mice were divided into two groups:those animals implanted s.c. with estradiol pellets and those without.Tumors were implanted using Matrigel (reduced factor) to enhance tumorincidence and promote tumor growth in the presence and absence ofestrogen. Glyceollins (or vehicle) were injected daily for 20 days.Measurable tumors were observed on Day 8 for both MCF-7 cells (FIG. 3)and BG-1 cells (FIG. 4). Tumors in all groups are measurable andsignificantly larger on Day 8 than on Day 0. Estrogen stimulated theformation of rapidly growing tumors in both MCF-7 and BG-1 implantedmice, reaching a maximal size of 3074±843 mm³ in MCF-7 and 3836±756 mm³in BG-1 implanted animals by day 20 of treatment. In the negativecontrol animals (without estrogen pellets or glyceollins), tumorincidence occurred on day 4 and tumors grew slowly with a maximal sizeof 899±24 mm³ for MCF-7 cells and 976±42 mm³ for BG-1 cells on day 20 oftreatment. In the Glyceollins I-III treated groups the growth of MCF-7and BG-1 tumors in the presence and absence of estrogen was suppressedby Glyceollins I-III treatment. Treatment with Glyceollins I-IIIsuppressed estrogen-stimulated tumor growth. On Day 20 of treatment,glyceollin-treated animals were not significantly different fromnegative control levels; tumor sizes of 1433±414 mm³ for MCF-7 (p=0.336)and 1031±96 mm³ for BG-1 (p=0.956) were observed. In the absence of E2,Glyceollins I-III stabilized growth of tumors to 536±41 mm³ in MCF-7cells and 532±55 mm³ in BG-1 tumors, thereby suppressing growth to belownegative control levels. These glyceollin-treated tumors weresignificantly smaller than negative control tumors by day 14 for MCF-7cells (p=0.003) and by day 12 for BG-1 cells (p=0.001). Tumors were allharvested on day 21 and sectioned for HE staining and forimmunohistochemistry for Ki67 staining and progesterone receptorexpression.

Example 6 Progesterone Receptor Immunochemistry

Tumor explants were resected at necropsy, fixed in 70% ethanol, embeddedin paraffin, and immunostained using a primary monoclonal antibody forhuman progesterone receptor (PR) (NCL-PGR, Novocastra,Newcastle-upon-Tyne, UK). Staining methods included antigen-retrievalwith citrate buffer (pH 6.0), biotinylated rabbit anti-mouse Fc antibodyas a linking reagent, alkaline phosphatase-conjugated streptavidin asthe label, and Vector Red as the chromogen (Vector Laboratories,Burlingame, Calif.). Cell staining was quantified by a computer-assistedcounting technique, using a grid filter to select cells for counting(Darvill et al., supra; Burow et al., supra). At least two microscopicfields were randomly selected for each tumor and 200 cells were countedat 40× magnification. Numbers of positively stained cells were expressedas a percentage of the total number examined. All measurements were madeblinded to treatment group.

Progesterone receptor expression is an estrogen-sensitive marker drivenby ER transactivation. In this study we used PR immunostaining toevaluate (a) whether glyceollin treatment alone was stimulating the ERas an agonist and (b) whether glyceollin treatment with estradiol (E2)was antagonizing ER activation. E2 treatment significantly increased PRexpression (C vs E2, p<0.05) while glyceollin alone did not (C vs Gly,p=0.92) (FIG. 5). Treatment with glyceollins, when given with E2,completely blocked E2 effects on PR expression in MCF-7 tumors (E2 vsE2+Gly, p<0.05) and partially antagonized E2 effects in BG1 tumors (C vsE2+Gly, p=0.16).

Example 7 Uterine Morphology

Uteri were removed at necropsy, weighed, fixed in 70% ethanol, sectionedtransversely through each uterine horn, embedded in paraffin, andstained with hematoxylin and eosin by routine procedures. Slides werephotographed at 2× and 40× magnification using a Nikon CoolPix E995digital camera (Melville, N.Y.). Uterine area, thickness, and epithelialheight were measured from digital images using public domain software(NIH Image v1.62; available athttp://rsb.info.nih.gov/nihimage/download.html). For epithelial height,three separate measurements were taken and the average was used for eachanimal. H&E-stained uteri were evaluated qualitatively for histologicchanges.

Data for epithelial height were subjected to one-way analysis ofvariance. All variables were evaluated for their distribution andequality of variances between groups. A two-tailed significance level of0.05 was chosen for all comparisons. Analyses were done using the SASstatistical package (version 6.08; SAS Institute, Cary, N.C.).

Mouse uteri were evaluated to assess whether glyceollin treatment hadestrogen-like effects on other reproductive tissues. Uterine weights aregiven in FIG. 6. Glyceollin combined with E2 did not significantlydecrease the uterine weight below the level measure for E2 alone.Uterine area, uterine diameter, and epithelial height were significantlyincreased by E2 (C vs E2, p<0.0001), but not glyceollin treatment (FIG.7). Glyceollin treatment in turn partially antagonized E2 effects on theuterus, significantly reducing uterine area and diameter (E2 vs E2+Gly,p<0.01). On histology, uteri from control and glyceollin-treated animalswere diffusely atrophic and could not be distinguished morphologically(FIG. 8). Superficial epithelial cells were predominantly cuboidal withround to oval nuclei, while stromal cells were densely packed with scantcytoplasm. Uteri from E2-treated mice were markedly larger withepithelial pseudostratification, stromal edema and hyperplasia, andincreased numbers of endometrial glands.

Data Analysis: Data for MCF-7N and BG-1 tumor size were analyzedseparately using repeated measures two-way ANOVA with treatment and timeas independent factors (SigmaStat 3.1). Data failed normality testingand so were rank transformed before analysis. Power for each of thesecomparisons (treatment, trial day, treatment×trial day) was 1.0.Post-hoc multiple pairwise comparisons testing using the Holm-Sidakmethod followed. Overall statistical significance level was set atp=0.05, but critical p levels for individual pairwise comparisons wereadjusted for the number of comparisons. Tumor sizes are reported astreatment group means±SEM.

All publications and patents mentioned in this specification are hereinincorporated by reference to the same extent as if each individualpublication or patent was specifically and individually indicated to beincorporated by reference.

The foregoing description and certain representative embodiments anddetails of the invention have been presented for purposes ofillustration and description of the invention. It is not intended to beexhaustive or to limit the invention to the precise forms disclosed. Itwill be apparent to practitioners skilled in this art that modificationsand variations may be made therein without departing from the scope ofthe invention.

1. A pharmaceutical composition for the treatment of breast cancer andovarian cancer, wherein said composition comprises isolated glyceollinin an amount effective for the therapeutic treatment of breast cancerand ovarian cancer.
 2. The composition of claim 1 wherein glyceollin isisolated from elicited soy.
 3. The composition of claim 2 wherein saidglyceollin isolated from elicited soy is Glyceollin I, II, and III. 4.The composition of claim 1 in which in the effective therapeutic amountof said glyceollin in said composition is selected on the basis of atreatment for breast cancer.
 5. The composition of claim 4 wherein saidtherapeutic amount of said glyceollin in said composition is 100 nM to50 μM.
 6. The composition of claim 1 in which in the effectivetherapeutic amount of said glyceollin in said composition is selected onthe basis of a treatment for ovarian cancer.
 7. The composition of claim4 wherein said therapeutic amount of said glyceollin in said compositionis 100 nM to 50 μM.
 8. A composition for preventing, minimizing, orreversing the development or growth of breast cancer or ovarian cancerin a female individual comprising glyceollin, wherein said glyceollin ispresent in said composition in an amount effective to prevent, minimize,or reverse the development or growth of breast cancer or ovarian cancerin a the individual upon adminstration to said individual.
 9. Thecomposition of claim 8 wherein said glyceollin is administered in anamount of 1 mg/kg/individual to 50 mg/kg/individual.
 10. The compositionof claim 8 wherein said glyceollin is present in an amount sufficient toaugment prevention or minimization of development or growth of breastcancer or ovarian cancer provided by SERMs upon administration of saidcomposition to a female individual.
 11. The composition of claim 10,wherein said glyceollin is present in said composition in an amounteffective to prevent or minimize uterotrophic effects induced by a SERMin said individual.
 12. The composition of claim 1 in which saidcomposition is in a form of a product for oral delivery, said productform being selected from a group consisting of a concentrate, driedpowder, liquid, capsule, pellet, pill, and a food supplement includinghealth bars.
 13. The composition of claim 1 in which said composition isin a form of a product for parenteral administration includingintravenous, intradermal, intramuscular, and subcutaneousadministration.
 14. The composition of claim 1 further comprisingcarriers, binders, diluents, and excipients.
 15. A method of inhibitingtumor growth comprising contacting a tumor with a composition comprisingglyceollin and determining that growth of said tumor has been inhibited.16. A method of preventing or treating cancer or tumor growth in afemale individual comprising administering to the individual acomposition comprising glyceollin and determining the development orgrowth of breast cancer or ovarian cancer has been prevented, minimized,or reversed.
 17. A method of inhibiting uterotrophic effects in a femaleindividual comprising administering to the individual a compositioncomprising glyceollin and determining that uterotrophic effects havebeen inhibited.
 18. A method of preventing uterotrophic effects in afemale individual comprising administering to the individual acomposition comprising glyceollin and determining that uterotrophiceffects have been prevented.